New human study with FrieslandCampina’s Vivinal GOS powder shows improved intestinal barrier function in obese adults

13 November 2018

The University of Nebraska in Lincoln (USA), Rush University Medical Center in Chicago (USA) and the University of Alberta in Edmonton (Canada) have recently completed a study into the effects of prebiotics, probiotics and synbiotics on intestinal barrier function and gut microbiota in obese adults. One of the results of the study was that consumption of galacto-oligosaccharides (Vivinal GOS powder) significantly reduces certain markers of gut permeability, indicating an improved intestinal barrier function.1

Mothers prefer infant formula containing Vivinal® Milk Fat

2 November 2018

Recently, FrieslandCampina Domo conducted a sensory study with about 100 mothers tasting an infant formula with Vivinal® Milk Fat blend 30 and one with vegetable oil. 61% of the mothers indicated their preference for the Vivinal® Milk Fat blend 30 containing formula over the infant formula containing vegetable oil.

Improving allergy formula acceptance

9 October 2018

Taste is a real challenge for allergy formulations. See how parents can give nutrition to their allergic child using revised hydrolysis technology that supports acceptance    

25% reduction in the use of fossil based energy sources for production of Vivinal® GOS

3 August 2018

Since its market launch in 2000, more than 160 million babies worldwide have been successfully nourished with our Vivinal® GOS (prebiotic) ingredient. It is an important ingredient in infant formula. Sustainability is an important part of the strategy of FrieslandCampina.  

FrieslandCampina’s new Human Milk Oligosaccharide ingredient, 2’-FL, obtains EU approval and GRAS status

8 May 2018

PRESS RELEASE FrieslandCampina DOMO’s new Human Milk Oligosaccharide (HMO) ingredient, 2’-fucosyllactose (2’-FL), has been officially certified to be used in infant formula in both European and U.S. markets. The ingredient has received EU novel food approval and achieved GRAS (Generally Recognised as Safe) status from the Food and Drug Administration (FDA) in the U.S. These authorisations are an important step forward in the plan of FrieslandCampina to launch its first human milk oligosaccharide by the end of the year.